Solara Active Pharma Sciences reports consolidated Q2 FY25 net profit at Rs. 8.01 Cr
Solara Active Pharma Sciences has reported total income of Rs. 347.27 crores during the period ended September 30, 2024
Solara Active Pharma Sciences has reported total income of Rs. 347.27 crores during the period ended September 30, 2024
Product basket comprises 2,047 medicines and 300 surgical devices covering all major therapeutic groups
Infant Mortality Rate in Bihar came down from 42 to 27 in 2020, and in Jharkhand, from 34 to 25 in 2020
Indoco is comprehensively working on the remedial action plan
The authorization of bortezomib will enhance the company’s ability to deliver advanced cancer solutions in Southeast Asia
The product is an additional formulation of Cresemba Capsule 100 mg and Cresemba Intravenous Infusion 200 mg
Tremelimumab (Imjudo) in combination with Durvalumab (Imfinzi) is indicated for the treatment of patients with unresectable hepatocellular carcinoma
Palivizumab (Synagis) is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by RSV in children at high risk for RSV disease
Professor G. D. Yadav is one of India’s most prolific and accomplished engineering-scientists, holding the prestigious National Science Chair from the Government of India
Aragen Life Sciences is the first Indian CRDMO to receive SBTi approval
Subscribe To Our Newsletter & Stay Updated